BIOCRYST PHARMACEUTICALS INC
Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$8.47
-0.59%
Alpha Vantage · 10/30/2026
One-year price history
Adjusted daily closes · 252 observations · as of Oct 30, 2026
1 month
+4.3%
3 months
-3.9%
6 months
-7.8%
1 year
+16.8%
Year to date
+8.6%
52-week range
$6.24 – $11.11
Fundamental snapshot
Latest reported period: Jun 30, 2026
Market cap
$2.16B
P/E
-5.6
P/B
-4.8
P/S
2.3
Revenue
$940.61M
Net income
-$384.67M
Diluted EPS
-1.49
Gross margin
97.80%
Net margin
-40.90%
Return on equity
101.60%
Total debt
$836.65M
Cash
$155.45M
Free cash flow
$373.38M
Latest eight reported quarters
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Jun 30, 2026 | $218.25M | $78.4M | 98.20% | 35.90% | $104.13M |
| Mar 31, 2026 | $156.41M | -$721.81M | 96.60% | -461.50% | -$62.19M |
| Dec 31, 2025 | $406.56M | $245.85M | 97.70% | 60.50% | $291.16M |
| Sep 30, 2025 | $159.4M | $12.9M | 98.60% | 8.10% | $40.28M |
| Jun 30, 2025 | $163.35M | $5.09M | 98.30% | 3.10% | $41.12M |
| Mar 31, 2025 | $145.53M | $32K | 96.90% | 0.00% | -$27.66M |
| Dec 31, 2024 | $131.53M | -$26.8M | 95.30% | -20.40% | -$5.89M |
| Sep 30, 2024 | $117.09M | -$14.03M | 97.20% | -12.00% | $8.19M |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Recent BCRX news
All market newsNo ticker-linked stories are in the current archive.